ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

amivantamab

Also written as “Amivantamab”, “Amivantamab IV” and “Amivantamab SC”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Squamous Cell Carcinoma of Head and Neck · Carcinoma, Hepatocellular · Stomach Neoplasms, led by 2 companies.

Drug pageAmivantamab: every studyAll 31 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 23, 202016 company-led studies, 13 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnsonits history only1512 open or runningphase 3since Jul 23, 2020Nov 18, 2015Dec 31, 2026phase 1 · NCT02609776
AstraZenecaits history only11 open or runningphase 2since Mar 24, 2023Mar 24, 2023Oct 1, 2027phase 2 · NCT05801029

Also a collaborator on its studies: Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 2 earlier studies, Nov 18, 2015 to Aug 30, 2019.

  1. Jun 9, 2019Named amivantamabINNProposed as its International Nonproprietary Name in WHO's List 121
  2. Jul 23, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT04487080 · 1,074 enrolled · United States, Argentina, Australia and more
  3. Jun 23, 2021Phase 2 study in Stomach NeoplasmsJohnson & Johnson · NCT04945733 · 62 enrolled · Japan
  4. Jul 30, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT04988295 · 776 enrolled · United States, Argentina, Belgium and more
  5. May 17, 2022Phase 2 study in Colorectal NeoplasmsJohnson & Johnson · NCT05379595 · 225 planned · United States, Belgium, Canada and more
  6. May 19, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT05388669 · 418 enrolled · United States, Argentina, Australia and more
  7. Aug 3, 2022Phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT05488314 · 57 enrolled · United States, Brazil, Canada and more
  8. Dec 8, 2022Phase 2 study in Carcinoma, HepatocellularJohnson & Johnson · NCT05653427 · 18 enrolled · China
  9. Mar 24, 2023AstraZeneca’s first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to AstraZenecaAstraZeneca · NCT05801029 · 60 enrolled · Hong Kong, Malaysia, Singapore and more
  10. Nov 2, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT06120140 · 305 enrolled · United States, Argentina, Brazil and more
  11. Apr 23, 2024Phase 2 study in Squamous Cell Carcinoma of Head and NeckJohnson & Johnson · NCT06385080 · 287 planned · United States, China, France and more
  12. Jul 29, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT06532032 · 12 enrolled · United States, Taiwan, Turkey (Türkiye) and more
  13. Oct 28, 2024Phase 3 study in Colorectal NeoplasmsJohnson & Johnson · NCT06662786 · 1,000 planned · United States, Belgium, Brazil and more
  14. Dec 20, 2024Phase 3 study in Colorectal NeoplasmsJohnson & Johnson · NCT06750094 · 700 planned · United States, Australia, Belgium and more
  15. Dec 1, 2025Phase 3 study in Squamous Cell Carcinoma of Head and NeckJohnson & Johnson · NCT07276399 · 600 planned · United States, Australia, Austria and more

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT02609776
  2. Feb 12, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT04077463
  3. Apr 27, 2027Primary completion: phase 2 study in Colorectal NeoplasmsJohnson & Johnson · NCT05379595
  4. Apr 28, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT05488314

TargetBeta

EGFR →MET →read by rule
“A human bispecific antibody targeting both epidermal growth factor receptor EGFR and hepatocyte growth factor receptor (HGFR; cMet), ”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor; Hepatocyte growth factor receptor inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
HS-20117Hansoh Pharmaceutical Groupphase 33
pamvatamigruleBetta Pharmaceuticalsphase 25
TQB2922Sino Biopharmaceuticalphase 25
TQB6411Sino Biopharmaceuticalphase 23
Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101ruleVelaVigo Caymanphase 21
Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412ruletavotek-biotherapeuticsphase 12
HS-20122Hansoh Pharmaceutical Groupphase 12
Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902ruleBeOne Medicinesphase 11
Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446Johnson & Johnsonphase 11
HLX48Fosun Pharmaphase 11

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07276399Squamous Cell Carcinoma of Head and Neck · United States, Australia, Austria and more3RecruitingJohnson & JohnsonJun 18, 2029600
NCT06750094Colorectal Neoplasms · United States, Australia, Belgium and more3RecruitingJohnson & JohnsonDec 15, 2027700
NCT06662786Colorectal Neoplasms · United States, Belgium, Brazil and more3RecruitingJohnson & JohnsonDec 15, 20281,000
NCT06532032Carcinoma, Non-Small-Cell Lung · United States, Taiwan, Turkey (Türkiye) and more2CompletedJohnson & JohnsonMay 14, 202612
NCT06385080Squamous Cell Carcinoma of Head and Neck · United States, China, France and more2RecruitingJohnson & JohnsonDec 27, 2032287
NCT06120140Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more2Active, not recruitingJohnson & JohnsonMay 31, 2027305
NCT05801029Carcinoma, Non-Small-Cell Lung · Hong Kong, Malaysia, Singapore and more2Active, not recruitingAstraZenecaOct 1, 202760
NCT05653427Carcinoma, Hepatocellular · China2TerminatedJohnson & JohnsonOct 10, 202318
NCT05488314Carcinoma, Non-Small-Cell Lung · United States, Brazil, Canada and more2Active, not recruitingJohnson & JohnsonApr 28, 202757
NCT05388669Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingJohnson & JohnsonJan 3, 2024418
NCT05379595Colorectal Neoplasms · United States, Belgium, Canada and more2RecruitingJohnson & JohnsonApr 27, 2027225
NCT04988295Carcinoma, Non-Small-Cell Lung · United States, Argentina, Belgium and more3Active, not recruitingJohnson & JohnsonJul 10, 2023776
NCT04945733Stomach Neoplasms · Japan2TerminatedJohnson & JohnsonJul 3, 202362
NCT04487080Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingJohnson & JohnsonAug 11, 20231,074
NCT04077463Carcinoma, Non-Small-Cell Lung · United States, China, France and more1Active, not recruitingJohnson & JohnsonFeb 12, 2027701
NCT02609776Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more1Active, not recruitingJohnson & JohnsonDec 31, 2026751

How it is read

Names in the registry

  • “Amivantamab”, 15 entries
  • “Amivantamab IV”, 2 entries
  • “Amivantamab SC”, 1 entry
  • “Amivantamab Intravenous”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.